The biotech company Abivax has raised $750 million to develop obefazimod, an oral treatment for ulcerative colitis.
This molecule is the result of over 20 years of research led by Prof. Jamal Tazi at the Institut de Génétique moléculaire de Montpellier (IGMM).
This innovative oral treatment showed a significant clinical remission rate and a good safety profile in phase III trials, with commercialization expected as early as 2027.
Source: CNRS Innovation
